Preliminary Classification:

Proposed Class:

Subclass:

NOTE: "All applicants are requested to include a preliminary classification on newly filed patent applications. The preliminary classification, preferably class and subclass designations, should be identified in the upper right-hand comer of the letter of transmittal accompanying the application papers, for example 'Proposed Class 2, subclass 129.' " M.P.E.P. § 601, 7th ed.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop Patent Application **Commissioner for Patents** P.O. Box 1450 Alexandria VA 22313-1450

NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of

Inventor(s): MATTI SALMI and JARI SELENIUS

WARNING: 37 C.F.R. § 1.41(a)(1) points out:

"(a) A patent is applied for in the name or names of the actual inventor or inventors.

"(1) The inventorship of a nonprovisional application is that inventorship set forth in the oath or declaration as prescribed by § 1.63, except as provided for in § 1.53(d)(4) and § 1.63(d). If an oath or declaration as prescribed by § 1.63 is not filed during the pendency of a nonprovisional application, the inventorship is that inventorship set forth in the application papers filed pursuant to § 1.53(b), unless a petition under this paragraph accompanied by the fee set forth in § 1.17(i) is filed supplying or changing the name or names of the inventor or inventors." For (title):

TITLE: RENDERING ELECTRONIC PRESENTATIONS TO PRINTED SURFACE

EXPRESS MAILING UNDER 37 C.F.R. § 1.10*

(Express Mail label number is mandatory.) (Express Mail certification is optional.)

I hereby certify that this paper, along with any document referred to, is being deposited with the United States Postal Service on this date November 25, 2003 ____, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 as "Express Mail Post Office to Addressee" Mailing Label EV 30 3 7 1 2 7 4 5 US

Margery B. Hood

(type or print name of person mailing paper)

WARNING: Certificate of mailing (first class) or facsimile transmission procedures of 37 C.F.R. 1.8 cannot be used to obtain a date of mailing or transmission for this correspondence.

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).

> "Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

> > (New Application Transmittal [4-1]-page 1 of 15)

1. Type of Application

			• •				,	٠.
This	new	apr	nica	tion.	ıs	tor	ain)

(check one applicable item below)

K	Original (nonprovisional)
	Design
	☐ Plant
WARNIN	G: Do not use this transmittal for a completion in the U.S. of an International Application under 35 U.S.C. § 371(c)(4), unless the International Application is being filed as a divisional, continuation or continuation-in-part application.
WARNIN	G: Do not use this transmittal for the filing of a provisional application.
7	f one of the following 3 items apply, then complete and attach ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF A PRIOR U.S. APPLICATION CLAIMED and a NOTIFICATION IN PARENT APPLICATION OF THE FILING OF THIS CONTINUATION APPLICATION.
	Divisional.
	Continuation.
	Continuation-in-part (C-I-P).

2. Benefit of Prior U.S. Application(s) (35 U.S.C. §§ 119(e), 120, or 121)

NOTE: "A nonprovisional application or international application designating the United States of America may claim an invention disclosed in one or more prior-filed copending nonprovisional applications or international applications designating the United States of America. In order for an application to claim the benefit of a prior-filed copending nonprovisional application or international application designating the United States of America, each prior-filed application must name as an inventor at least one inventor named in the later-filed application and disclose the named inventor's invention claimed in at least one claim of the later-filed application in the manner provided by the first paragraph of 35 U.S.C. 112. In addition, each prior-filed application must be:

- (i) An international application entitled to a filing date in accordance with PCT Article 11 and designating the United States of America; or
 - (ii) Complete as set forth in § 1.51(b); or
- (iii) Entitled to a filing date as set forth in § 1.53(b) or § 1.53(d) and include the basic filing fee set forth in § 1.16; or
- (iv) Entitled to a filing date as set forth in § 1.53(b) and have paid therein the processing and retention fee set forth in § 1.21(f) within the time period set forth in § 1.53(f).

37 C.F.R. § 1.78(a)(1).

WARNING: If an application claims the benefit of the filing date of an earlier filed application under 35 U.S.C. §§ 120, 121 or 365(c), the 20-year term of that application will be based upon the filing date of the earliest U.S. application that the application makes reference to under 35 U.S.C. §§ 120, 121 or 365(c). (35 U.S.C. § 154(a)(2) does not take into account, for the determination of the patent term, any application on which priority is claimed under 35 U.S.C. §§ 119, 365(a) or 365(b).) For a c-i-p application, applicant should review whether any claim in the patent that will issue is supported by an earlier application and, if not, the applicant should consider canceling the reference to the earlier filed application. The term of a patent is not based on a claim-by-claim approach.

See Notice of April 14, 1995, 60 Fed. Reg. 20,195, at 20,205.

WARNING: 37 C.F.R. § 1.78(a)(2) deals with the time in which the claim for the benefit of an earlier filing date must be made and states:

(2)(i) Except for a continued prosecution application filed under § 1.53(d), any nonprovisional: application or international application designating the United States of America claiming the benefit of one or more prior-filed copending nonprovisional applications or international applications designating the United States of America must contain or be amended to contain a reference to each such prior-filed application, identifying it by application number (consisting of the series code and serial number) or international application number and international filing date and indicating the relationship of the applications. Cross references to other related applications may be made when appropriate (see § 1.14).

- (ii) This reference must be submitted during the pendency of the later-filed application. If the later-filed application is an application filed under 35 U.S.C. 111(a), this reference must also be submitted within the later of four months from the actual filing date of the later-filed application or sixteen months from the filing date of the prior-filed application. If the later-filed application is a nonprovisional application which entered the national stage from an international application after compliance with 35 U.S.C. 371, this reference must also be submitted within the later of four months from the date on which the national stage commenced under 35 U.S.C. 371(b) or (f) in the later-filed international application or sixteen months from the filing date of the prior-filed application. These time periods are not extendable. Except as provided in paragraph (a)(3) of this section, the failure to timely submit the reference required by 35 U.S.C. 120 and paragraph (a)(2)(i) of this section is considered a waiver of any benefit under 35 U.S.C. 120, 121, or 365(c) to such prior-filed application. The time periods in this paragraph do not apply if the later-filed application is:
 - (A) An application for a design patent;
 - (B) An application filed under 35 U.S.C. 111(a) before November 29, 2000; or
- (C) A nonprovisional application which entered the national stage after compliance with 35 U.S.C. 371 from an international application filed under 35 U.S.C. 363 before November 29, 2000.
- (iii) If the later-filed application is a nonprovisional application, the reference required by this paragraph must be included in an application data sheet (§ 1.76), or the specification must contain or be amended to contain such reference in the first sentence following the title.
- (iv) The request for a continued prosecution application under § 1.53(d) is the specific reference required by 35 U.S.C. 120 to the prior-filed application. The identification of an application by application number under this section is the identification of every application assigned that application number necessary for a specific reference required by 35 U.S.C. 120 to every such application assigned that application number."

NOTE: If the new application being transmitted is a divisional, continuation or a continuation-in-part of a parent case, or where the parent case is an International Application which designated the U.S., or benefit of a prior provisional application is claimed, then check the following item and complete and attach ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICA-TION(S) CLAIMED.

The new application being transmitted claims the benefit of prior U.S. application(s). Enclosed are ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.

3. Papers Enclosed

A.	Required for filing date under 37 C.F.R. § 1.53(b) (Regular) or 37 C.F.R. § 1.153 (Design) Application
	11 Pages of specification

4_ Pages of claims

6 Sheets of drawing

WARNING: DO NOT submit original drawings. A high quality copy of the drawings should be supplied when filing a patent application. The drawings that are submitted to the Office must be on strong, white, smooth, and non-shiny paper and meet the standards according to § 1.84. If corrections to the drawings are necessary, they should be made to the original drawing and a high-quality copy of the corrected original drawing then submitted to the Office. Only one copy is required or desired. For comments on proposed then-new 37 C.F.R. § 1.84, see Notice of March 9, 1988 (1990 O.G. 57-62).

been assigned to the application. If this information is provided, it must be placed on the front of each sheet and centered within the top margin." (complete the following, if applicable) The enclosed drawing(s) are photograph(s). NOTE: 37 C.F.R. 1.84 "(b) Photographs. "(1) Black and white. Photographs, including photocopies of photographs, are not ordinarily permitted in utility and design patent applications. The Office will accept photographs in utility and design patent applications, however, if photographs are the only practicable medium for illustrating the claimed invention. For example, photographs or photomicrographs of: electrophoresis gels, blots (e.g., immunological, western, Southern, and northern), auto radiographs, cell cultures (stained and unstained), histological tissue cross sections (stained and unstained), animals, plants, in vivo imaging, thin layer chromatography plates, crystalline structures, and, in a design patent application, ornamental effects, are acceptable. If the subject matter of the application admits of illustration by a drawing, the examiner may require a drawing in place of the photograph. The photographs must be of sufficient quality so that all details in the photographs are reproducible in the printed patent. "(2) Color photographs. Color photographs will be accepted in utility and design patent applications if the conditions for accepting color drawings and black and white photographs have been satisfied. See paragraphs (a)(2) and (b)(1) of this section." The enclosed drawing(s) are in color. Three (3) sets of color drawings and a "PETITION TO ACCEPT COLOR DRAWING(S)" are attached. 37 C.F.R. §§ 1.84(a)(2) and 1.84(b). NOTE: 37 C.F.R. 1.84(a) "(2) Color. On rare occasions, color drawings may be necessary as the only practical medium by which to disclose the subject matter sought to be patented in a utility or design patent application or the subject matter of a statutory invention registration. The color drawings must be of sufficient quality such that all details in the drawings are reproducible in black and white in the printed patent. Color drawings are not permitted in international applications (see PCT Rule 11.13), or in an application, or copy thereof, submitted under the Office electronic filing system. The Office will accept color drawings in utility or design patent applications and statutory invention registrations only after granting a petition filed under this paragraph explaining why the color drawings are necessary. Any such petition must include the following: (i) The fee set forth in § 1.17(h); (ii) Three (3) sets of color drawings; (iii) A black and white photocopy that accurately depicts, to the extent possible, the subject matter shown in the color drawing; and (iv) An amendment to the specification to insert (unless the specification contains or has been previously amended to contain) the following language as the first paragraph of the brief description of the drawings: The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee." formal ☐ informal B. Other Papers Enclosed Pages of declaration and power of attorney Pages of abstract Other

"Identification of drawings. Identifying indicia, if provided, should include the title of the invention, inventor's name and application number, or docket number (if any) if an application number has not

NOTE:

Amendment to claims ☐ Cancel in this applications claims ☐ Cancel in this applications claims ☐ Cancel in this applications claims ☐ Cancel in this applications claims ☐ Learning the filing purposes.) ☐ Add the claims shown on the attached amendment. (Claims added have been numbered consecutively following the highest numbered original claims.) ☐ Preliminary Amendment ☐ Riformation Disclosure Statement (37 C.F.R. § 1.98) ☐ Information Disclosure Statement (37 C.F.R. § 1.98) ☐ Riformation Disclosure Statement shall be considered by the Office if filed by the application which is 1.53(d); ☐ Within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); ☐ Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; ☐ Norder to ensure consideration of information previously submitted but which has not been considered in the parent application, an applicant must resubmit the information, complying with 37 C.F.R. § 1.97 and 37 C.F.R. § 1.98, in the continuing application filed under 37 C.F.R. § 1.53(b). See § 6098(3), M.P.E.P., 7th Edition, Rev. 1. ☐ Form PTO-1449 (PTO/SB/08A and 08B) ☐ Citations ☐ Declaration of Biological Deposit ☐ Submission of "Sequence Listing," computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequence. ☐ Authorization of Attorney(s) to Accept and Follow Instructions from Representative ☐ Special Comments ☐ Other ☐ Declaration or oath (including power of attorney) ☐ NOTE: A newly executed declaration is not required in a continuation or divisional application provided that the pnor nonprovisional application contained a declaration as required, the application being filed is the app	. Addi	tiona	l papers enclosed
calculating the filing purposes.) Add the claims shown on the attached amendment. (Claims added have been numbered consecutively following the highest numbered original claims.) Preliminary Amendment Information Disclosure Statement (37 C.F.R. § 1.98) NOTE: 37 C.F.R. § 1.97 (b) An information disclosure statement shall be considered by the Office if filed by the applicant within any one of the following time periods: (1) Within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); (2) Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; (3) Before the mailing of a first Office action on the ments; or WARNING: In order to ensure consideration of information previously submitted but which has not been considered in the parent application, an applicant must resubmit the information, complying with 37 C.F.R. § 1.97 and 37 C.F.R. § 1.98, in the continuing application filed under 37 C.F.R. § 1.53(b). See § 6998(3), M.F.E.P., 7th Edition, Rev. 1. Torm PTO-1449 (PTO/SB/08A and 08B) Citations Declaration of Biological Deposit Submission of "Sequence Listing," computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequence. Authorization of Attorney(s) to Accept and Follow Instructions from Representative Special Comments Other Declaration or oath (including power of attorney) NOTE: A newly executed declaration is not required in a continuation or divisional application provided that the prior nonprovisional application contained a declaration as required, the application being filed is by all or fewer than all the inventors named in the prior application, there is no new matter in the application being filed, and a copy of the executed declaration filed in the prior application being filed, and a copy of the executed declaration filed in the prior application being filed, and a copy of the executed m		Ar	mendment to claims
been numbered consecutively following the highest numbered original claims.) Preliminary Amendment Information Disclosure Statement (37 C.F.R. § 1.98) NOTE: 37 C.F.R. \$ 1.97 (b) An information disclosure statement shall be considered by the Office if filed by the applicant within any one of the following time periods: (1) Within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); (2) Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; (3) Before the mailing of a first Office action on the merits; or WARNING: In order to ensure consideration of information previously submitted but which has not been considered in the panent application, an applicant must resubmit the information, complying with 37 C.F.R. § 1.97 and 37 C.F.R. § 1.98, in the continuing application filed under 37 C.F.R. § 1.53(b). See § 609B(3), M.P.E.P., 7th Edition, Rev. 1. In Form PTO—1449 (PTO/SB/08A and 08B) Citations Declaration of Biological Deposit Submission of "Sequence Listing," computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequence. Authorization of Attorney(s) to Accept and Follow Instructions from Representative Special Comments Other Declaration or oath (including power of attorney) NOTE: A newly executed declaration is not required in a continuation or divisional application perioded that the prior nonprovisional application contained a declaration as required, the application being filed is by all or fewer than all the inventors named in the prior application, there is no new matter in the application being filed, and a copy of the executed declaration have an en inventors of the application being filed, and a copy of the executed declaration, are not inventors of the application being filed, and a copy of the executed declaration, there is no new matter in the application must be filed accompanied by			calculating the filing fee. (At least one original independent claim must be
NOTE: 37 C.F.R. § 1.97 (b) An information disclosure statement shall be considered by the Office if filed by the applicant within any one of the following time periods: (1) Within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); (2) Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; (3) Before the mailing of a first Office action on the merits; or WARNING: In order to ensure consideration of information previously submitted but which has not been considered in the parent application, an applicant must resubmit the information, complying with 37 C.F.R. § 1.93 end 37 C.F.R. § 1.93, in the continuing application filed under 37 C.F.R. § 1.53(b). See § 609B(3), M.P.E.P., 7th Edition, Rev. 1. [X] Form PTO—1449 (PTO/SB/08A and 08B) [X] Citations [Declaration of Biological Deposit [Submission of "Sequence Listing," computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequence. [Authorization of Attorney(s) to Accept and Follow Instructions from Representative [Special Comments [Other] [Other] [Other] [Other] [Other] [A newly executed declaration is not required in a continuation or divisional application provided that the prior norprovisional application contained a declaration filed in the prior application being filed, and a copy of the executed declaration filed in the prior application being filed as by all or fewer than all the inventors named in the prior application, there is no new matter in the application being filed, and a copy of the executed declaration filed in the prior application being filed and celaration in indication thereion that it was signed) is submitted. The copy must be accompanied by a statement requesting deletion of the names of person(s) who are not inventors of the application being filed. If the declaration in the prior application on a root prior to the decla			been numbered consecutively following the highest numbered original
NOTE: 37 C.F.R. § 1.97 (b) An information disclosure statement shall be considered by the Office if filed by the applicant within any one of the following time periods: (1) Within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); (2) Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; (3) Before the mailing of a first Office action on the merits; or WARNING: In order to ensure consideration of information previously submitted but which has not been considered in the parent application, an applicant must resubmit the information, complying with 37 C.F.R. § 1.79 and 37 C.F.R. § 1.96, in the continuing application filed under 37 C.F.R. § 1.53(b). See § 6098(3), M.P.E.P., 7th Edition, Rev. 1. [X] Form PTO-1449 (PTO/SB/08A and 08B) [X] Citations [Declaration of Biological Deposit [Declaration of Biological Deposit [Declaration of Attorney(s) to Accept and Follow Instructions from Representative [Declaration of Attorney(s) to Accept and Follow Instructions from Representative [Declaration or oath (including power of attorney) NOTE: A newly executed declaration is not required in a continuation or divisional application perioded that the prior nonprovisional application contained a declaration as required, the application being filed by all or fewer than all the inventors named in the prior application from matter in the application being filed, and a copy of the executed declaration filed in the prior application (showing the signature or an indication thereon that it was signed is submitted. The copy must be accompanied by a statement requesting deletion of the names of person(s) who are not inventors of the application being filed. If the declaration in the prior application must be filed accompanied by a copy of the decision granting § 1.47 status or, if a nonsigning person under § 1.47 has subsequently poined in a prior application, then a copy of the subsequently		Pr	eliminary Amendment
the applicant within any one of the following time periods: (1) Within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); (2) Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; (3) Before the mailing of a first Office action on the merits; or WARNING: In order to ensure consideration of information previously submitted but which has not been considered in the parent application, an applicant must resubmit the information, complying with 37 C.F.R. § 1.93 and 37 C.F.R. § 1.98, in the continuing application filed under 37 C.F.R. § 1.53(b). See § 609B(3), M.P.E.P., 7th Edition, Rev. 1. [2] Form PTO—1449 (PTO/SB/08A and 08B) [3] Citations [4] Declaration of Biological Deposit [5] Submission of "Sequence Listing," computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequence. [6] Authorization of Attorney(s) to Accept and Follow Instructions from Representative [7] Special Comments [7] Other [8] Declaration or oath (including power of attorney) NOTE: A newly executed declaration is not required in a continuation or divisional application being filed is by all or fewer than all the inventors named in the prior application, there is no new matter in the application being filed, and a copy of the executed declaration filed in the prior application being filed, and a copy of the recuted declaration filed in the prior application being filed, and a copy of the formal perior application file accompanied by a statement requesting deletion of the names of person(s) who are not inventors of the application being filed. If the declaration in the prior application was filed under § 1.47 has subsequently pioned in a prior application, then a copy of the subsequently provided in a prior application file during the subsequently provided for in a prior application in the accompanied by \$ 1.63 (c) of each inve	X	Int	formation Disclosure Statement (37 C.F.R. § 1.98)
application under § 1.53(d); (2) Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; (3) Before the mailing of a first Office action on the merits; or WARNING: In order to ensure consideration of information previously submitted but which has not been considered in the parent application, an applicant must resubmit the information, complying with 37 C.F.R. § 1.97 and 37 C.F.R. § 1.98, in the continuing application filed under 37 C.F.R. § 1.53(b). See § 609B(3), M.P.E.P., 7th Edition, Rev. 1. [X] Form PTO—1449 (PTO/SB/08A and 08B) [X] Citations [Declaration of Biological Deposit [Submission of "Sequence Listing," computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequence. [Authorization of Attorney(s) to Accept and Follow Instructions from Representative [Special Comments [Other [Other [Other oath (including power of attorney) NOTE: A newly executed declaration is not required in a continuation or divisional application being filed is by all or fewer than all the inventors named in the prior application, there is no new matter in the application being filed, and a copy of the executed declaration filed in the prior application being filed is by all or fewer than all the inventors named in the prior application, there is no new matter in the application being filed, and a copy of the executed declaration filed in the prior application being filed. If the declaration in the prior application was filed under § 1.47, then a copy of the accompanied by a statement requesting deletion of the names of person(s) who are not inventors of the application being filed. If the declaration in the prior application was filed under § 1.47, then a copy of the declaration must be filed accompanied by a copy of the decision granting § 1.47 status or, if a nonsigning person under § 1.47 has subsequently joined in a prior application. It hen a copy of the absolution together wit		the ap	oplicant within any one of the following time periods:
international application; (3) Before the mailing of a first Office action on the merits; or WARNING: In order to ensure consideration of information previously submitted but which has not been considered in the parent application, an applicant must resubmit the information, complying with 37 C.F.R. § 1.93 and 37 C.F.R. § 1.98, in the continuing application filed under 37 C.F.R. § 1.53(b). See § 609B(3), M.P.E.P., 7th Edition, Rev. 1. Torm PTO-1449 (PTO/SB/08A and 08B)		app	olication under § 1.53(d);
 WARNING: In order to ensure consideration of information previously submitted but which has not been considered in the parent application, an applicant must resubmit the information, complying with 37 c.F.R. § 1.97 and 37 c.F.R. § 1.97 in the continuing application filed under 37 c.F.R. § 1.53(b). See § 609B(3), M.P.E.P., 7th Edition, Rev. 1. □ Form PTO-1449 (PTO/SB/08A and 08B) □ Citations □ Declaration of Biological Deposit □ Submission of "Sequence Listing," computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequence. □ Authorization of Attorney(s) to Accept and Follow Instructions from Representative □ Special Comments □ Other i. Declaration or oath (including power of attorney) NOTE: A newly executed declaration is not required in a continuation or divisional application provided that the prior nonprovisional application contained a declaration as required, the application being filed is by all or fewer than all the inventors named in the prior application, there is no new matter in the application being filed, and a copy of the executed declaration filed in the prior application (showing the signature or an indication thereon that it was signed) is submitted. The copy must be accompanied by a statement requesting deletion of the names of person(s) who are not inventors of the application being filed. If the declaration in the prior application was filed under § 1.47 status or, if a nonsigning person under § 1.47 has subsequently joined in a prior application, then a copy of the subsequently executed declaration must be filed. See 37 C.F.R. § § 1.63(d)(1)–(3). NOTE: A declaration filed to complete an application must be executed, identify the specification to which it is directed, identify each inventor by full name including family name and at least one given name, without abbreviation tog		inte	ernational application;
considered in the parent application, an applicant must resubmit the information, complying with 37 C.F.R. § 1.97 and 37 C.F.R. § 1.53(b). See § 609B(3), M.P.E.P., 7th Edition, Rev. 1. Torm PTO-1449 (PTO/SB/08A and 08B)			
□ Citations □ Declaration of Biological Deposit □ Submission of "Sequence Listing," computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequence. □ Authorization of Attorney(s) to Accept and Follow Instructions from Representative □ Special Comments □ Other □ Declaration or oath (including power of attorney) NOTE: A newly executed declaration is not required in a continuation or divisional application provided that the prior nonprovisional application contained a declaration as required, the application being filed is by all or fewer than all the inventors named in the prior application, there is no new matter in the application being filed, and a copy of the executed declaration filed in the prior application (showing the signature or an indication thereon that it was signed) is submitted. The copy must be accompanied by a statement requesting deletion of the names of person(s) who are not inventors of the application being filed. If the declaration in the prior application was filed under § 1.47, then a copy of that declaration was the filed accompanied by a copy of the decision granting § 1.47 status or, if a nonsigning person under § 1.47 has subsequently joined in a prior application, then a copy of the subsequently executed declaration must be filed. See 37 C.F.R. §§ 1.63(d)(1)–(3). NOTE: A declaration filed to complete an application must be executed, identify the specification to which it is directed, identify each inventor by full name including family name and at least one given name, without abbreviation together with any other given name or initial, and the residence, post office address and country or citizenship of each inventor, and state whether the inventor is a sole or joint inventor. 37 C.F.R. § 1.63(a)(1)–(4). NOTE: "The inventorship of a nonprovisional application is that inventorship set forth in the oath or declaration as prescribed by § 1.63 is not filed during the pendency of a nonprovisional application, the	WARNIN	3	considered in the parent application, an applicant must resubmit the information, complying with B7 C.F.R. § 1.97 and 37 C.F.R. § 1.98, in the continuing application filed under 37 C.F.R. § 1.53(b).
Declaration of Biological Deposit Submission of "Sequence Listing," computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequence. Authorization of Attorney(s) to Accept and Follow Instructions from Representative Special Comments Other The Declaration or oath (including power of attorney) NOTE: A newly executed declaration is not required in a continuation or divisional application provided that the prior nonprovisional application contained a declaration as required, the application being filed is by all or fewer than all the inventors named in the prior application, there is no new matter in the application being filed, and a copy of the executed declaration filed in the prior application (showing the signature or an indication thereon that it was signed) is submitted. The copy must be accompanied by a statement requesting deletion of the names of person(s) who are not inventors of the application being filed. If the declaration in the prior application was filed under § 1.47, then a copy of that declaration must be filed accompanied by a copy of the decision granting § 1.47 status or, if a nonsigning person under § 1.47 has subsequently joined in a prior application, then a copy of the subsequently executed declaration must be filed. See 37 C.F.R. §§ 1.63(d)(1)–(3). NOTE: A declaration filed to complete an application must be executed, identify the specification to which it is directed, identify each inventor by full name including family name and at least one given name, without abbreviation together with any other given name or initial, and the residence, post office address and country or citizenship of each inventor, and state whether the inventor is a sole or joint inventor. 37 C.F.R. § 1.63(a)(1)–(4). NOTE: "The inventorship of a nonprovisional application is that inventorship set forth in the oath or declaration as prescribed by § 1.62, except as provided for in § 1.53(d) and § 1.63(d). If an oath or declaration is pres	X	Fc	orm PTO-1449 (PTO/SB/08A and 08B)
□ Submission of "Sequence Listing," computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequence. □ Authorization of Attorney(s) to Accept and Follow Instructions from Representative □ Special Comments □ Other Other Other A newly executed declaration is not required in a continuation or divisional application provided that the prior nonprovisional application contained a declaration as required, the application being filed is by all or fewer than all the inventors named in the prior application, there is no new matter in the application being filed, and a copy of the executed declaration filed in the prior application (showing the signature or an indication thereon that it was signed) is submitted. The copy must be accompanied by a statement requesting deletion of the names of person(s) who are not inventors of the application being filed. If the declaration in the prior application was filed under § 1.47, then a copy of that declaration must be filed accompanied by a copy of the decision granting § 1.47 status or, if a nonsigning person under § 1.47 has subsequently joined in a prior application, then a copy of the subsequently executed declaration filed to complete an application must be executed, identify the specification to which it is directed, identify each inventor by full name including family name and at least one given name, without abbreviation together with any other given name or initial, and the residence, post office address and country or citizenship of each inventor, and state whether the inventor is a sole or joint inventor. 37 C.F.R. § 1.63(a)(1)-(4). NOTE: "The inventorship of a nonprovisional application is that inventorship set forth in the oath or declaration as prescribed by § 1.62, except as provided for in § 1.53(d)(4) and § 1.63(d). If an oath or declaration as prescribed by § 1.63 is not filed during the pendency of a nonprovisional application, the inventorship is that inventorship set forth in the ap	X	Ci	tations
pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequence. Authorization of Attorney(s) to Accept and Follow Instructions from Representative Special Comments Other Declaration or oath (including power of attorney) NOTE: A newly executed declaration is not required in a continuation or divisional application provided that the prior nonprovisional application contained a declaration as required, the application being filed is by all or fewer than all the inventors named in the prior application, there is no new matter in the application being filed, and a copy of the executed declaration filed in the prior application (showing the signature or an indication thereon that it was signed) is submitted. The copy must be accompanied by a statement requesting deletion of the names of person(s) who are not inventors of the application being filed. If the declaration in the prior application was filed under § 1.47, then a copy of that declaration must be filed accompanied by a copy of the decision granting § 1.47 status or, if a nonsigning person under § 1.47 has subsequently joined in a prior application, then a copy of the subsequently executed declaration filed to complete an application must be executed, identify the specification to which it is directed, identify each inventor by full name including family name and at least one given name, without abbreviation together with any other given name or initial, and the residence, post office address and country or citizenship of each inventor, and state whether the inventor is a sole or joint inventor. 37 C.F.R. § 1.63(a)(1)-(4). NOTE: "The inventorship of a nonprovisional application is that inventorship set forth in the oath or declaration as prescribed by § 1.62, except as provided for in § 1.53(d)(4) and § 1.63(d). If an oath or declaration is prescribed by § 1.63 is not filed during the pendency of a nonprovisional application, the inventorship is that inventorship set forth in the application papers filed pursuant to § 1.		De	eclaration of Biological Deposit
Special Comments Other Declaration or oath (including power of attorney) NOTE: A newly executed declaration is not required in a continuation or divisional application provided that the prior nonprovisional application contained a declaration as required, the application being filed is by all or fewer than all the inventors named in the prior application, there is no new matter in the application being filed, and a copy of the executed declaration filed in the prior application (showing the signature or an indication thereon that it was signed) is submitted. The copy must be accompanied by a statement requesting deletion of the names of person(s) who are not inventors of the application being filed. If the declaration in the prior application was filed under § 1.47, then a copy of that declaration must be filed accompanied by a copy of the decision granting § 1.47 status or, if a nonsigning person under § 1.47 has subsequently joined in a prior application, then a copy of the subsequently executed declaration must be filed. See 37 C.F.R. §§ 1.63(d)(1)–(3). NOTE: A declaration filed to complete an application must be executed, identify the specification to which it is directed, identify each inventor by full name including family name and at least one given name, without abbreviation together with any other given name or initial, and the residence, post office address and country or citizenship of each inventor, and state whether the inventor is a sole or joint inventor. 37 C.F.R. § 1.63(a)(1)–(4). NOTE: "The inventorship of a nonprovisional application is that inventorship set forth in the oath or declaration as prescribed by § 1.62, except as provided for in § 1.53(d)(4) and § 1.63(d). If an oath or declaration as prescribed by § 1.63 is not filed during the pendency of a nonprovisional application, the inventorship is that inventorship set forth in the application papers filed pursuant to § 1.53(b), unless a petition under this paragraph accompanied by the fee set forth in § 1.17(i) is filed supplying or		ре	ertaining thereto for biotechnology invention containing nucleotide and/or
Other Declaration or oath (including power of attorney) NOTE: A newly executed declaration is not required in a continuation or divisional application provided that the prior nonprovisional application contained a declaration as required, the application being filed is by all or fewer than all the inventors named in the prior application, there is no new matter in the application being filed, and a copy of the executed declaration filed in the prior application (showing the signature or an indication thereon that it was signed) is submitted. The copy must be accompanied by a statement requesting deletion of the names of person(s) who are not inventors of the application being filed. If the declaration in the prior application was filed under § 1.47, then a copy of that declaration must be filed accompanied by a copy of the decision granting § 1.47 status or, if a nonsigning person under § 1.47 has subsequently joined in a prior application, then a copy of the subsequently executed declaration must be filed. See 37 C.F.R. §§ 1.63(d)(1)–(3). NOTE: A declaration filed to complete an application must be executed, identify the specification to which it is directed, identify each inventor by full name including family name and at least one given name, without abbreviation together with any other given name or initial, and the residence, post office address and country or citizenship of each inventor, and state whether the inventor is a sole or joint inventor. 37 C.F.R. § 1.63(a)(1)–(4). NOTE: "The inventorship of a nonprovisional application is that inventorship set forth in the oath or declaration as prescribed by § 1.62, except as provided for in § 1.53(d)(4) and § 1.63(d). If an oath or declaration as prescribed by § 1.63 is not filed during the pendency of a nonprovisional application, the inventorship is that inventorship set forth in the application papers filed pursuant to § 1.53(b), unless a petition under this paragraph accompanied by the fee set forth in § 1.17(i) is filed supplying or changing the pame			
NOTE: A newly executed declaration is not required in a continuation or divisional application provided that the prior nonprovisional application contained a declaration as required, the application being filed is by all or fewer than all the inventors named in the prior application, there is no new matter in the application being filed, and a copy of the executed declaration filed in the prior application (showing the signature or an indication thereon that it was signed) is submitted. The copy must be accompanied by a statement requesting deletion of the names of person(s) who are not inventors of the application being filed. If the declaration in the prior application was filed under § 1.47, then a copy of that declaration must be filed accompanied by a copy of the decision granting § 1.47 status or, if a nonsigning person under § 1.47 has subsequently joined in a prior application, then a copy of the subsequently executed declaration must be filed. See 37 C.F.R. §§ 1.63(d)(1)–(3). NOTE: A declaration filed to complete an application must be executed, identify the specification to which it is directed, identify each inventor by full name including family name and at least one given name, without abbreviation together with any other given name or initial, and the residence, post office address and country or citizenship of each inventor, and state whether the inventor is a sole or joint inventor. 37 C.F.R. § 1.63(a)(1)–(4). NOTE: "The inventorship of a nonprovisional application is that inventorship set forth in the oath or declaration as prescribed by § 1.63 is not filed during the pendency of a nonprovisional application, the inventorship is that inventorship set forth in the application papers filed pursuant to § 1.53(b), unless a petition under this paragraph accompanied by the fee set forth in § 1.17(i) is filed supplying or changing the name		Sp	pecial Comments
NOTE: A newly executed declaration is not required in a continuation or divisional application provided that the prior nonprovisional application contained a declaration as required, the application being filed is by all or fewer than all the inventors named in the prior application, there is no new matter in the application being filed, and a copy of the executed declaration filed in the prior application (showing the signature or an indication thereon that it was signed) is submitted. The copy must be accompanied by a statement requesting deletion of the names of person(s) who are not inventors of the application being filed. If the declaration in the prior application was filed under § 1.47, then a copy of that declaration must be filed accompanied by a copy of the decision granting § 1.47 status or, if a nonsigning person under § 1.47 has subsequently joined in a prior application, then a copy of the subsequently executed declaration must be filed. See 37 C.F.R. §§ 1.63(d)(1)–(3). NOTE: A declaration filed to complete an application must be executed, identify the specification to which it is directed, identify each inventor by full name including family name and at least one given name, without abbreviation together with any other given name or initial, and the residence, post office address and country or citizenship of each inventor, and state whether the inventor is a sole or joint inventor. 37 C.F.R. § 1.63(a)(1)–(4). NOTE: "The inventorship of a nonprovisional application is that inventorship set forth in the oath or declaration as prescribed by § 1.62, except as provided for in § 1.53(d)(4) and § 1.63(d). If an oath or declaration as prescribed by § 1.63 is not filed during the pendency of a nonprovisional application, the inventorship is that inventorship set forth in the application papers filed pursuant to § 1.53(b), unless a petition under this paragraph accompanied by the fee set forth in § 1.17(i) is filed supplying or changing the name		Ot	her
NOTE: A newly executed declaration is not required in a continuation or divisional application provided that the prior nonprovisional application contained a declaration as required, the application being filed is by all or fewer than all the inventors named in the prior application, there is no new matter in the application being filed, and a copy of the executed declaration filed in the prior application (showing the signature or an indication thereon that it was signed) is submitted. The copy must be accompanied by a statement requesting deletion of the names of person(s) who are not inventors of the application being filed. If the declaration in the prior application was filed under § 1.47, then a copy of that declaration must be filed accompanied by a copy of the decision granting § 1.47 status or, if a nonsigning person under § 1.47 has subsequently joined in a prior application, then a copy of the subsequently executed declaration must be filed. See 37 C.F.R. §§ 1.63(d)(1)–(3). NOTE: A declaration filed to complete an application must be executed, identify the specification to which it is directed, identify each inventor by full name including family name and at least one given name, without abbreviation together with any other given name or initial, and the residence, post office address and country or citizenship of each inventor, and state whether the inventor is a sole or joint inventor. 37 C.F.R. § 1.63(a)(1)–(4). NOTE: "The inventorship of a nonprovisional application is that inventorship set forth in the oath or declaration as prescribed by § 1.62, except as provided for in § 1.53(d)(4) and § 1.63(d). If an oath or declaration as prescribed by § 1.63 is not filed during the pendency of a nonprovisional application, the inventorship is that inventorship set forth in the application papers filed pursuant to § 1.53(b), unless a petition under this paragraph accompanied by the fee set forth in § 1.17(i) is filed supplying or changing the name	. Decl	aratio	on or oath (including power of attorney)
is directed, identify each inventor by full name including family name and at least one given name, without abbreviation together with any other given name or initial, and the residence, post office address and country or citizenship of each inventor, and state whether the inventor is a sole or joint inventor. 37 C.F.R. § 1.63(a)(1)-(4). NOTE: "The inventorship of a nonprovisional application is that inventorship set forth in the oath or declaration as prescribed by § 1.62, except as provided for in § 1.53(d)(4) and § 1.63(d). If an oath or declaration as prescribed by § 1.63 is not filed during the pendency of a nonprovisional application, the inventorship is that inventorship set forth in the application papers filed pursuant to § 1.53(b), unless a petition under this paragraph accompanied by the fee set forth in § 1.17(f) is filed supplying or changing the name	NOTE:	A nev the pi by all applic the si by a s being declai perso	why executed declaration is not required in a continuation or divisional application provided that first nonprovisional application contained a declaration as required, the application being filed is or fewer than all the inventors named in the prior application, there is no new matter in the ration being filed, and a copy of the executed declaration filed in the prior application (showing gnature or an indication thereon that it was signed) is submitted. The copy must be accompanied statement requesting deletion of the names of person(s) who are not inventors of the application filed. If the declaration in the prior application was filed under § 1.47, then a copy of that ration must be filed accompanied by a copy of the decision granting § 1.47 status or, if a nonsigning in under § 1.47 has subsequently joined in a prior application, then a copy of the subsequently
as prescribed by § 1.62, except as provided for in § 1.53(d)(4) and § 1.63(d). If an oath or declaration as prescribed by § 1.63 is not filed during the pendency of a nonprovisional application, the inventorship is that inventorship set forth in the application papers filed pursuant to § 1.53(b), unless a petition under this paragraph accompanied by the fee set forth in § 1.17(f) is filed supplying or changing the name	NOTE:	A dec is dire abbre count	claration filed to complete an application must be executed, identify the specification to which it cted, identify each inventor by full name including family name and at least one given name, without viation together with any other given name or initial, and the residence, post office address and ry or citizenship of each inventor, and state whether the inventor is a sole or joint inventor.
·		as pre as pre is that this p	escribed by § 1.62, except as provided for in § 1.53(d)(4) and § 1.63(d). If an oath or declaration scribed by § 1.63 is not filed during the pendency of a nonprovisional application, the inventorship inventorship set forth in the application papers filed pursuant to § 1.53(b), unless a petition under aragraph accompanied by the fee set forth in § 1.17(i) is filed supplying or changing the name

	Enc	losed
	Exe	cuted by
		(check all applicable boxes)
		inventor(s).
		legal representative of inventor(s). 37 C.F.R. §§ 1.42 or 1.43.
		joint inventor or person showing a proprietary interest on behalf of inventor who refused to sign or cannot be reached.
		☐ This is the petition required by 37 C.F.R. § 1.47 and the statement required by 37 C.F.R. § 1.47 is also attached. See item 13 below for fee.
X	Not	Enclosed.
ti n	he U.S nay be	the filing is a completion in the U.S. of an International Application or where the completion of B. application contains subject matter in addition to the International Application, the application is treated as a continuation or continuation-in-part, as the case may be, utilizing ADDED PAGE EW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION CLAIMED.
		Application is made by a person authorized under 37 C.F.R. § 1.41(c) on behalf of all the above named inventor(s).
(The c	ieclai	ration or oath, along with the surcharge required by 37 C.F.R. § 1.16(e) can be filed subsequently).
		☐ Showing that the filing is authorized. (not required unless called into question. 37 C.F.R. § 1.41(d))
6. Inven	torsh	pip Statement
WARNIN	01	the named inventors are each not the inventors of all the claims an explanation, including the wnership of the various claims at the time the last claimed invention was made, should be ubmitted.
The inv	rento	rship for all the claims in this application are:
	The	e same.
		or
		t the same. An explanation, including the ownership of the various claims at time the last claimed invention was made,
		is submitted.
		will be submitted.
7. Lang	uage	
,	An En require	colication including a signed oath or declaration may be filed in a language other than English. It is glish translation of the non-English language application and the processing fee of \$130.00 and by 37 C.F.R. § 1.17(k) is required to be filed with the application, or within such time as may by the Office. 37 C.F.R. § 1.52(d).
(X)	En	glish
	No	n-English
		The attached translation includes a statement that the translation is accurate. 37 C.F.R. § 1.52(d).

X	An assignment of th	e invention to <u>Nokia Corpor</u>	cation
		separate	
	🗓 will follow.		
		ed with a new application, send two separa " Notice of May 4, 1990 (1114 O.G. 77-7	
WARNING		TIFICATE UNDER 37 C.F.R. § 3.73(b)" mu ed by an assignee. Notice of April 30, 19:	
	This is a 🗌 continu	uation divisional application	and the assignment
	document for the pa	arent application 0 /	was filed
	on		
			Reel
			Frame
9. Certifi	ed Copy		
Certified	d copy(ies) of applica	tion(s)	
Counti	У	Appln. No.	Filed
Counti	у	Appln. No.	Filed
Count	у	Appln. No.	Filed
from which	h priority is claimed		
	is (are) attached.		
	will follow.		
NOTE: 3	7 C.F.R. § 1.55 Claim for	foreign priority.	
	"(a) • • •		
	during the pendency of the of the application or sixte period is not extendable. It as well as any foreign application for which intellectual property authorized.	tion filed under 35 U.S.C. 111(a), the claim e application, and within the later of four men en months from the filing date of the price. The claim must identify the foreign applicate polication for the same subject matter and ch priority is claimed, by specifying the a crity), day, month, and year of its filing. The ation under 35 U.S.C. 111(a) if the application	nonths from the actual filing date or foreign application. This time tion for which priority is claimed, having a filing date before that application number, country (or time periods in this paragraph
	(A) A design application; (or	
	(B) An application filed be	fore November 29, 2000.	
	priority under 35 U.S.C. paragraph (a) of this section 119(a)-(d) or 365(a) is presclaim may be accepted if the number, country (or intelligent	ecepted in accordance with the provisions 119(a)-(d) or 365(a) not presented within it is considered to have been waived. If a cented after the time period provided by plus claim identifying the prior foreign applica ectual property authority), and the day, mention to accept a delayed claim for prices against hy:	n the time period provided by claim for priority under 35 U.S.C. paragraph (a) of this section, the ation by specifying its application north, and year of its filing was

8. Assignment

- (1) The claim under 35 U.S.C. 119(a)-(d) or 365(a) and this section to the prior foreign application, unless previously submitted;
 - (2) The surcharge set forth in § 1.17(t); and
- (3) A statement that the entire delay between the date the claim was due under paragraph (a)(1) of this section and the date the claim was filed was unintentional. The Commissioner may require additional information where there is a question whether the delay was unintentional."

NOTE: 37 C.F.R. § 1.63 Oath or declaration.

- "(a) An oath or declaration filed under § 1.51(b)(2) as a part of a nonprovisional application must:
- (c) Unless such information is supplied on an application data sheet in accordance with § 1.76, the oath or declaration must also identify:
 - (2) Any foreign application for patent (or inventor's certificate) for which a claim for priority is made pursuant to § 1.55, and any foreign application having a filing date before that of the application on which priority is claimed, by specifying the application number, country, day, month, and year of its filing."

The foreign application forming the basis for the claim for priority must be referred to in the oath or declaration. 37 C.F.R. § 1.55(a) and 1.63.

NOTE: This item is for any foreign priority for which the application being filed directly relates. If any parent U.S. application or International Application from which this application claims benefit under 35 U.S.C. § 120 is itself entitled to priority from a prior foreign application, then complete item 18 on the ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.

10. Fee Calculation (37 C.F.R. § 1.16)

A. X Regular application

		CL	AIMS AS	S FILED		
Number filed		N	umber Ex	ktra	Rate	Basic Fee 37 C.F.R. § 1.16(a) 2\$750.00 \$770.0
Total Claims (37 C.F.R.						
§ 1.16(c))	32	- 20 =	12	×	\$ 18.00	216.00
Independent Claims (37 C.F.R. § 1.16(b))	6	- 3 =	3	×	86.00 XXXXXXXX	258.00
Multiple dependent if any (37 C.F.R.		. ,,		+	\$280.00	
		ancelling ext				l.
☐ Fee for	extra (claims is not	being p	aid at thi	is time.	
prior to the e	expiratio		eriod set fo			ms cancelled by amendment, and Trademark Office in any
		Filing Fo	ee Calcul	lation		\$ <u>1,244.00</u>

		• •		
В.		Design applicatio (\$330.00—37 C.F		
			Filing Fee Calculation	\$
C	. [Plant application (\$520.00—37 C.F		\$
44	A	namian of Curall Fu	Filing fee calculation	D
11.	_	sertion of Small En		
				entity under 37 C.F.R. § 1.27
NC	IIE:	declaration thereof or by the national phase and s	payment as a small entity of the	ntity status, whether by a written specific basic filing fee or the fee for the entry into
		organization) should m to be accorded small and must, in order to a make an assertion of the	nake a determination, pursuant to entity status based on the definition establish small entity status for the entitlement to small entity status,	son, small business concern or nonprofit paragraph (f) of this section, of entitlement ons set forth in paragraph (a) of this section, purpose of paying small entity fees, actually in the manner set forth in paragraphs (c)(1) which such small entity fees are to be paid.
		(1) Assertion by writi to small entity statu	ng. Small entity status may be est s. A written assertion must:	ablished by a written assertion of entitlement
		(i) Be clearly iden	tifiable;	
		(ii) Be signed (see	paragraph (c)(2) of this section);	and
		is a small entity, o While no specific	r that small entity status is entitled words or wording are required to	ity status, such as by stating that applicant to be asserted for the application or patent. assert small entity status, the intent to assert er to comply with the assertion requirement.
				n. The written assertion can be signed by:
		(i) One of the parts § 3.73(b) of this of	es identified in § 1.33(b) (e.g., an hapter notwithstanding, who can	attorney or agent registered with the Office), also file the written assertion;
		or declaration has	the individuals identified as an in not been submitted), notwithstand t to the exception under § 1.33(b	ventor (even though a § 1.63 executed oath ling § 1.33(b)(4), who can also file the written b) of this part; or
		(iii) An assignee o chapter, but the pa § 1.33(b) of this p	artial assignee cannot file the asser	ithstanding §§ 1.33(b)(3) and 3.73(b) of this tion without resort to a party identified under
		party, of the exact a (g), (h), or (k), or one (a)(4), or (a)(5), will b	amount of one of the small entity of the small entity basic national	g or basic national fee. The payment, by any basic filing fees set forth in §§ 1.16(a), (f), fees set forth in §§ 1.492(a)(1), (a)(2), (a)(3), entitlement to small entity status even if the tly selected in error.
		national fee under balance of the sm	paragraph (c)(3) of this section ti	payment of a small entity basic filing or basic hat is not applicable to that application, any that application will be due along with the 1.16(l).
		(ii) The payment of (whether in the ex	any small entity fee other than tho act fee amount or not) will not be	se set forth in paragraph (c)(3) of this section treated as a written assertion of entitlement

(New Application Transmittal [4-1]-page 9 of 15)

to small entity status and will not be sufficient to establish small entity status in an application

or a patent."

WAHNING:	as a small entity must be specifically established by an assertion in each related, continuing and reissue application in which status is appropriate and desired. Status as a small entity in one application or patent does not affect the status of any other application or patent, regardless of the relationship of the applications or patents. The refilting of an application under § 1.53 as a continuation, divisional, or continuation-in-part application (including a continued prosecution application under § 1.53(d)), or the filing of a reissue application, requires a new assertion as to continued entitlement to small entity status for the continuing or reissue application."
WARNING:	"Small entity status must not be established when the person or persons signing the statement can unequivocally make the required self-certification." M.P.E.P., § 509.03 (emphasis added).
	(complete the following, if applicable)
	Status as a small entity was asserted in the prior application
	, filed on, from which benefit
	is being claimed for this application under:
	35 U.S.C. § 119(e) 120 121 365(c)
	and which status as a small entity is still proper and asserted for this application.
	☐ A copy of the written assertion of small entity filed in the prior application is included.
es foi	refund based on establishment of small entity status, of a portion of fees timely paid in full prior to tablishing status as a small entity may only be obtained if an assertion under § 1.27(c) and a request r a refund of the excess amount are filed within three months of the date of the timely payment of e full fee. The three-month time period is not extendable under § 1.136. 37 C.F.R. § 1.28(a).
	Filing Fee Calculation (50% of A, B or C above)
	\$
12. Requ	uest for International-Type Search (37 C.F.R. § 1.104(d))
	(complete, if applicable)
	Please prepare an international-type search report for this application at the time when national examination on the merits takes place.

13.	Fee	e Pay	ment Being Made at This Time	
	X	No	t Enclosed	
			No filing fee is to be paid at this time. (This and the surcharge required by 37 C.F.R. subsequently.)	§ 1.16(e) can be paid
) End	closed	
			Filing fee	\$
			Recording assignment (\$40.00; 37 C.F.R. § 1.21(h)) (See attached "COVER SHEET FOR ASSIGNMENT ACCOMPANYING NEW APPLICATION".)	\$
			Petition fee for filing by other than all the inventors or person on behalf of the inventor where inventor refused to sign or cannot be reached (\$130.00; 37 C.F.R. §§ 1.47 and 1.17(i))	\$
			For processing an application with a specification in a non-English language (\$130.00; 37 C.F.R. §§ 1.52(d) and 1.17(i))	\$
			Processing and retention fee (\$130.00; 37 C.F.R. §§ 1.53(d) and 1.21(l))	\$
			Fee for international-type search report (\$40.00; 37 C.F.R. § 1.21(e))	\$
N	OTE:	failing 37 C.F. either t	I.R. § 1.21(I) establishes a fee for processing and retaining any applied to complete the application pursuant to 37 C.F.R. § 1.53(f) and the land 1.78(a)(1), indicate that in order to obtain the benth basic filing fee must be paid, or the processing and retention 1 year from notification under § 53(f).	this, as well as the changes to refit of a prior U.S. application,
			Total fees enclosed	\$
14.	Me	thod	of Payment of Fees	
		Att	ached is a 🔲 check 🔲 money order in the amount	of \$
		l Aut	thorization is hereby made to charge the amount of	f \$
			to Deposit Account No.	
			to Credit card as shown on the attached credit cartion form PTO-2038.	d information authoriza-
W.	ARNIN	VG: Ci	redit card information should not be included on this form as it	may become public.
			arge any additional fees required by this paper or the manner authorized above.	credit any overpayment
			A duplicate of this paper is attached.	

15. Authorization to Charge Additional Fees

WARNING: If no fees are to be paid on filing, the following items should not be completed. Accurately count claims, especially multiple dependent claims, to avoid unexpected high charges, WARNING: if extra claim charges are authorized. WARNING: Even though small entity status is accorded where the wrong type of small entity basic filing fee or basic national fee is selected but the exact amount of the fee is paid, applicant still needs to pay the correct small entity amount for the basic filing or basic national fee where selection of the wrong type of fee results in a deficiency. While an accompanying general authorization to charge any additional fees suffices to pay the balance due of the proper small entity basic filing or basic national fee, specific authorizations to charge fees under § 1.17 or extension of time fees do not suffice to pay any balance due of the proper small entity basic filing or basic national fee because they do not actually authorize payment of small entity amounts. Changes To Implement the Patent Business Goals; Final Rule [Fed. Reg.: September 8, 2000, pages 54603-54683, at 54611; OG: October 3, 2000, pages 14-39]. The Office is hereby authorized to charge, in the manner shown above, the following additional fees that may be required by this paper and during the entire pendency of this application. 37 C.F.R. § 1.16(a), (f) or (g) (filing fees) 37 C.F.R. § 1.16(b), (c) and (d) (presentation of extra claims) NOTE: Because additional fees for excess or multiple dependent claims not paid on filing or on later presentation must only be paid or these claims cancelled by amendment prior to the expiration of the time period set for response by the PTO in any notice of fee deficiency (37 C.F.R. § 1.16(d)), it might be best not to authorize the PTO to charge additional claim fees, except possibly when dealing with amendments after final action. 37 C.F.R. § 1.16(e) (surcharge for filing the basic filing fee and/or declaration on a date later than the filing date of the application) 37 C.F.R. § 1.17(a)(1)-(5) (extension fees pursuant to § 1.136(a)). 37 C.F.R. § 1.17 (application processing fees) NOTE: ". . . A written request may be submitted in an application that is an authorization to treat any concurrent or future reply, requiring a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. An authorization to charge all required fees, fees under § 1.17, or all required extension of time fees will be treated as a constructive petition for an extension of time in any concurrent or future reply requiring a petition for an extension of time under this paragraph for its timely submission. Submission of the fee set forth in § 1.17(a) will also be treated as a constructive petition for an extension of time in any concurrent reply requiring a petition for an extension of time under this paragraph for its timely submission." 37 C.F.R. § 1.136(a)(3). 37 C.F.R. § 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 C.F.R. § 1.311(b)) NOTE: Section 1.311(b) provides that an authorization to charge the issue fee (§ 1.18) to a deposit account

may be filed in an individual application only after the mailing of the notice of allowance. Accordingly, general authorizations to pay fees and specific authorizations to pay the issue fee that are filed prior to the mailing of a notice of allowance will generally not be treated as requesting payment of the issue fee and will not be given effect to act as a reply to the notice of allowance. Applicant, when paying the issue fee, should submit a new authorization to charge fees, such as by completing box 6b on the current PTOL-85B form. Where no reply to the notice of allowance is received, the application will stand abandoned notwithstanding the presence of general authorizations to pay fees or a specific authorization to pay the issue fee that were submitted prior to mailing of the notice of allowance. Where an attempt is made to pay the issue fee but an incorrect amount is submitted, § 1.311(b)(1), or where the Office's issue fee transmittal form (currently PTOL-85(B)) is completed by applicant and submitted, § 1.311(b)(2), in reply to a notice of allowance, an exception will be made. Such submissions will operate as a request to charge the issue fee to any deposit account identified in a previously filed (i.e., submitted prior to the mailing of the notice of allowance) authorization to charge fees, and will be allowed to act as payment of the correct issue fee. § 1.311(b). See also the change to § 1.26(b). Notice of September 8, 2000, Fed. Reg. 54603-54683, at 54646 and 54647.

NOTE: 37 C.F.R. § 1.28(b) requires "Notification of any change in status resulting in loss of entitlement to small entity status must be filed in the application . . . prior to paying, or at the time of paying, . . . the issue fee. . . " From the wording of 37 C.F.R. § 1.28(b), (a) notification of change of status must be made even if the fee is paid as "other than a small entity" and (b) no notification is required if the change

Customer No.

004955

	is to another small entity.	
16. Ins	structions as to Overpayr	ment
NOTE:	a reasonable time, nor will the pa	ollars or less will not be returned unless specifically requested within lyer be notified of such amounts; amounts over twenty-five dollars may lested, by credit to a deposit account." 37 C.F.R. § 1.26(a).
	Credit Account No	
] Refund	
		$\mathcal{L}_{\mathcal{L}}}}}}}}}}$
		Thuis Merine
		SIGNATURE OF PRACTITIONER
Reg. No	D. 31,391	Francis J. Maguire
		Ware, Fressola, Van Der Stuys & Adolphson LLP
Tel. No.	(203) 261-1234	(type or print name of attorney)
	· 203 201-1234	755 Main Street, P.O. Box 224
		P.O. Address

Monroe, Connecticut 06468

	incorp	oration by reference of added pages
	pri sta the	neck the following item if the application in this transmittal claims the benefit of for U.S. application(s) (including an international application entering the U.S. age as a continuation, divisional or C-I-P application) and complete and attache ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF RIOR U.S. APPLICATION(S) CLAIMED)
		Plus Added Pages for New Application Transmittal Where Benefit of Prior U.S. Application(s) Claimed
		Number of pages added
		Plus Added Pages for Papers Referred to in Item 4 Above
		Number of pages added
		Plus added pages deleting names of inventor(s) named in prior application(s) who is/are no longer inventor(s) of the subject matter claimed in this application.
		Number of pages added
		Plus "Assignment Cover Letter Accompanying New Application"
		Number of pages added
X	State	ment Where No Further Pages Added
	•	no further pages form a part of this Transmittal, then end this Transmittal with is page and check the following item)
	\mathbf{x}	This transmittal ends with this page.